Evidence map›Paper›PMID 40636241›Full record

ArticleEuropean journal of case reports in internal medicine2025

Unexpected Falsely High Vancomycin Concentrations in a Patient with Endocarditis During Routine Therapeutic Drug Monitoring.

Laura Galán-Caballero, María Rosario Salas-Butrón, Daniel Lozano-Martín, Iván Alejandro Díaz-Rengifo, Isabel Ortega-Madueño, Lucia Diaz-Garcia, Ana Isabel Terleira-Fernández

Abstract read
In one paragraph

Article in European journal of case reports in internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Laura Galán-CaballeroDepartment of Clinical Pharmacology, Hospital Clínico San Carlos; IdISSC, Madrid, Spain.
María Rosario Salas-ButrónDepartment of Clinical Pharmacology, Hospital Clínico San Carlos; IdISSC, Madrid, Spain.
Daniel Lozano-MartínDepartment of Clinical Pharmacology, Central de la Defensa "Gómez Ulla" Hospital, Madrid, Spain.
Iván Alejandro Díaz-RengifoDepartment of Clinical Pharmacology, Hospital Clínico San Carlos; IdISSC, Madrid, Spain.
Isabel Ortega-MadueñoDepartment of Clinical Analysis, Hospital Clínico San Carlos, Instituto de Medicina del Laboratorio, Madrid, Spain.
Lucia Diaz-GarciaDepartment of Clinical Pharmacology, IdiPAZ, La Paz University Hospital, School of Medicine, Autonomous University of Madrid, Madrid, Spain.
Ana Isabel Terleira-FernándezDepartment of Clinical Pharmacology, Hospital Clínico San Carlos; IdISSC, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Vancomycin is a glycopeptide antibiotic indicated for the treatment of infections caused by methicillin-resistant Case description: An 87-year-old female was admitted with diagnosis of endocarditis. She was started on antibiotic therapy with intravenous vancomycin. The first vancomycin level registered in our hospital was 36.4 μg/ml. Because this value exceeded the critical threshold (15-20 μg/ml) the prescription was interrupted. New vancomycin concentration tests were indicated for the next days with 65.8 μg/ml, 73 μg/ml, 55.1 μg/ml, 77.9 μg/ml and 100 μg/ml results. Two samples were reanalysed in Hospital Universitario La Paz and were undetectable. Our Clinical Analysis Department found an analytical interference; however, the responsible molecule could not be identified, so the clinical team changed antibiotic treatment to daptomycin, and the infectious condition of the patient improved. Conclusions: It is recommended that clinicians have a high index of suspicion to investigate cases where drug concentrations do not correlate with clinical expectations. Healthcare professionals need to understand that occasional interference still occurs due to the binding of proteins. LEARNING POINTS: Unknown compounds or mechanisms may interfere with vancomycin assays.Assay interference should be suspected in patients with persistently high vancomycin levels who continue to deteriorate clinically.

Indexed as

immunoassayinterferencetherapeutic drug monitoringVancomycin

Identifiers

PMID40636241
PMCPMC12236687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.